Investment Rating - The report assigns a rating of "Outperform" for Sino Biopharmaceutical, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark by more than 10% [16]. Core Insights - Sino Biopharmaceutical achieved a revenue of RMB 31.8 billion in FY25, representing a year-on-year growth of 10%, with innovative drug revenue reaching RMB 15.2 billion, up 26% [6][1]. - The gross margin stood at 82.1%, an increase of 0.6 percentage points year-on-year, while R&D expenses rose to RMB 5.9 billion, reflecting a 15% increase [6][1]. - The net profit attributable to the parent company from sustainable operations was RMB 2.3 billion, marking a 22% increase year-on-year, and the non-IFRS net profit was RMB 4.5 billion, up 31% [6][1]. Segment Performance - The oncology segment generated revenue of RMB 13.2 billion, a growth of 23%, driven by strong sales of Yilishu (G-CSF), bemesumab (PD-L1), and other biosimilars [7][2]. - Revenue from liver disease and cardio-metabolic segments reached RMB 6.7 billion [10]. - The surgery and analgesia segment reported revenue of RMB 5.0 billion, reflecting a 13% increase [10]. - The respiratory and autoimmune segment generated revenue of RMB 2.8 billion [10]. Pipeline Catalysts - Multiple key data readouts are expected in 2026, including Phase II data for CLDN18.2 ADC in gastric cancer and CCR8 monoclonal antibody in pancreatic cancer [8][3]. - Additional data readouts include Phase III results for PPAR agonist in MASH and various metabolic candidates [8][3].

Investment Rating - The report maintains an "Outperform" rating for Sino Biopharmaceutical with a target price of HKD 10.87, reflecting a positive outlook on the company's performance [2][7]. Core Insights - Sino Biopharmaceutical achieved revenue of CNY 17.6 billion in 1H25, representing an 11% year-on-year increase, with a gross profit margin of 82.5% [3][12]. - The company's innovative drug sales reached CNY 7.8 billion, growing by 27% year-on-year, while generic drug revenue was CNY 9.8 billion, showing slight growth [4][13]. - The report highlights the strong growth drivers in oncology and surgery/analgesia segments, with oncology revenue at CNY 6.7 billion (+25% YoY) and surgery/analgesia revenue at CNY 3.1 billion (+20% YoY) [19]. Financial Performance - Revenue forecasts for 2025 and 2026 have been raised to CNY 33.4 billion and CNY 37.6 billion, respectively, due to expected growth in out-licensing revenue [17]. - Net profit attributable to parent shareholders is adjusted to CNY 4.8 billion and CNY 5.1 billion for FY25E and FY26E, respectively [17]. - The report indicates a projected diluted EPS of CNY 0.27 for 2025 and CNY 0.28 for 2026, with a gross profit margin expected to remain stable at 82.5% [10][17]. Clinical Pipeline and Growth Potential - The respiratory portfolio includes multiple candidates in clinical stages, with significant progress in PDE3/4 inhibitors for COPD and TSLP monoclonal antibodies for asthma [4][14]. - Six innovative products are expected to launch in 2025, including key products like TQB3616 (CDK2/4/6 inhibitor) and HER2 inhibitors [15][16]. - The report emphasizes the potential for out-licensing several innovative products in oncology and respiratory pipelines, which could enhance revenue streams [16].